CD37 Protein (AA 113-240) (hFc Tag)

Catalog No. ABIN7274150

Recombinant CD37 protein expressed in HEK-293 Cells.

Quick Overview for CD37 Protein (AA 113-240) (hFc Tag) (ABIN7274150)

Target: CD37 (TSPAN26) (Tetraspanin 26 (TSPAN26))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: HEK-293 Cells

Purity: > 95 % as determined by Bis-Tris PAGE,> 95 % as determined by HPLC

Product Details

Protein Characteristics: AA 113-240

Purification tag / Conjugate: This CD37 protein is labelled with hFc Tag.

Purpose: Human CD37 Protein

Sequence: Ala113-Asn240

Characteristics: Recombinant Human CD37 Protein is expressed from HEK293 with hFc (IgG1) tag at the N-Terminus.It contains Ala113-Asn240.

Sterility: 0.22 μm filtered

Endotoxin Level: Less than 1 EU per μg by the LAL method.

Biological Activity Comment: Human CD37 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.,The purity of Human CD37 is greater than 95% as determined by SEC-HPLC.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Dissolve the lyophilized protein in distilled water. It is recommended to resuspend at 0.5 mg/mL if the lyophilized powder is 100 μg or less, at 1 mg/mL for 500 μg or 1 mg lyophilized powder. Do not mix by vortex or vigorous shaking.

Buffer: Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.

Storage: -20 °C,-80 °C

Storage Comment: -20 to -80°C for 12 months as supplied from date of receipt.,-80°C for 3 months after reconstitution.,Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Expiry Date: 12 months

Target Details

Target: CD37 (TSPAN26) (Tetraspanin 26 (TSPAN26))

Alternative Name: CD37

Background: CD37 is a tetraspanin expressed prominently on the surface of B cells. It is an attractive molecular target exploited in the immunotherapy of B cell-derived lymphomas and leukemia. Currently, several monoclonal antibodies targeting CD37 as well as chimeric antigen receptor-based immunotherapies are being developed and investigated in clinical trials. Given the unique role of CD37 in the biology of B cells, it seems that CD37 constitutes more than a docking point for monoclonal antibodies, and targeting this molecule may provide additional benefit to relapsed or refractory patients.

Molecular Weight: 41.9 kDa. Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result.

UniProt: P11049

Pathways: Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response